Clinical trials: MASLD
Metabolic Dysfunction-associated Steatotic Liver Disease
Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity.
- Trial name
- MYO-MASLD (NCT06506513)
- Testing
- High-intensity interval training, Moderate intensity exercise training, Low intensity exercise training
- Where
- 2 sites in Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT07854782
- Testing
- ALN-CIDEB
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty…
- Trial name
- NCT07527910
- Testing
- ALN-PNP, Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- Regeneron Pharmaceuticals
MASLD, Fatty Liver
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver.
- Trial name
- NCT07646197
- Testing
- Peanut consumption
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Henry Ford Health System
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Cardiovascular Disease (CVD)
Cardiovascular Risk Assessment and Coronary Calcium Score in Thai MASLD Patients
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in Thailand and is strongly linked to metabolic risk factors such as obesity, diabetes, hypertension, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Cardiovascular Disease (CVD), Coronary Artery Calcification
- Trial name
- MASLD-CAC (NCT07865936)
- Where
- Thailand
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Watcharasak Chotiyaputta
Obstructive Sleep Apnea
Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea
The purpose of this study is to determine if vitamin D supplement and SGLT-2 inhibitor treatment combination can improve cardiovascular risks in patients with OSA and hypertension, on top of lifestyle modification, before…
- Trial name
- D3DOSA (NCT06690723)
- Testing
- Dapagliflozin (Forxiga), Vitamin D3 ( Colecalciferol), Vitamin D3 plus Dapagliflozin
- Where
- Malaysia
- Volunteers
- 160 people
- Sponsor
- University Malaysia Sarawak
Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases.
- Trial name
- MASH (NCT07201831)
- Testing
- No treatment given
- Where
- 5 sites in United States, Canada and 3 more
- Volunteers
- 1,330 people
- Sponsor
- Novo Nordisk A/S
Steatosis of Liver
Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical…
- Trial name
- MASLD (NCT07652892)
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Steatotic Liver Disease, Fibrosis of Liver
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of…
- Trial name
- MASLD-DIAB (NCT07270822)
- Testing
- Collaborative care pathways group, Control group without intervention
- Where
- 10 sites in France
- Volunteers
- 1,714 people
- Sponsor
- Hospices Civils de Lyon
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
NAFLD
Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
evaluate the combined effects of Rutin and Vitamin C versus Vitamin C alone on selected oxidative stress markers, inflammation, hepatic steatosis regression, and associated metabolic parameters in patients with MASLD
- Trial name
- NCT07310407
- Testing
- Rutin + Vitamin C, Vitamin C 500mg, Lifestyle Intervention
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Metabolic Dysfunction-associated Steatotic Liver Disease
Advanced Fibrosis Detection for MASLD in Primary Care
This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with…
- Trial name
- NCT07159386
- Testing
- EHR alert
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Medical University of South Carolina
Hepatocellular Carcinoma, Liver Cirrhosis
Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)
This prospective multicenter observational study evaluates the performance of a structured hepatocellular carcinoma (HCC) surveillance program in patients at increased risk of developing liver cancer.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- Screening HCC (NCT07764835)
- Volunteers
- 300 people
- Sponsor
- D'Or Institute for Research and Education
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus
Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.
Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement…
- Conditions
- MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus, Hypertension, Hyperlipidaemia
- Trial name
- NCT07025980
- Testing
- The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS
- Where
- Croatia
- Volunteers
- 114 people
- Sponsor
- Eva Cubric
MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
MASLD (Metabolic dysfunction-associated steatotic liver disease) is a condition where fat builds up in the liver. It is the most common cause of liver disease worldwide.
- Conditions
- MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASH With Fibrosis, Steatosis of Liver
- Trial name
- FLOURISH (NCT07013916)
- Testing
- fructose, glucose
- Where
- 2 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Metabolic Dysfunction-Associated Steatotic Liver Disease
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Study Title: Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Randomized Controlled Trial (D-FIB-MASLD) Objective: This study aims to assess…
- Trial name
- DEFIB-MASLD (NCT06920316)
- Testing
- Gro Health digital application
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- St. George's Hospital, London
Healthy, Simple Steatosis (SS)
New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
The goal of this observational study is to learn if some components of blood or exhaled breath can diagnose people having more fat in their livers than is normal, because of their poorer metabolic health (for example, because of…
- Conditions
- Healthy, Simple Steatosis (SS), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Trial name
- NCT06647095
- Testing
- D-Limonene Gelcaps, Fish Oil Concentrate, 1000 Mg Oral Capsule
- Where
- 2 sites in Czechia
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- General University Hospital, Prague
Metabolic Dysfunction-Associated Steatotic Liver Disease, Acute Coronary Syndromes (ACS)
MPV as a Predictor for ACS in Patients With MASLD
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume…
- Trial name
- MPV/ACS MASLD (NCT07487571)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)
Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Adults
The goal of this randomized control trial study is to compare an acceptance-based weight loss program with an occupational therapy behavioral lifestyle modification intervention in adults with metabolic associated-dysfunction…
- Trial name
- NCT06121999
- Testing
- Standard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Grand Valley State University